Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: Basic approaches and practical applications

International Journal of Pharmaceutics

Volumn 420, Issue 1, 2011, Pages 1-10

  Kawabata, Yohei ^a,b   Wada, Koichi ^b   Nakatani, Manabu ^b   Yamada, Shizuo ^a   Onoue, Satomi ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b NIPPON BOEHRINGER INGELHEIM CO LTD   (Japan)

Author keywords

Bioavailability; Biopharmaceutics classification system; Formulation development; Nanoparticle; Poorly water soluble drugs; Solid dispersion

Indexed keywords

1 BENZOYL 4 [(4,7 DIMETHOXY 1H PYRROLO[2,3 C]PYRIDIN 3 YL)OXOACETYL]PIPERAZINE; 1 [4 (5 BROMO 2 PYRIMIDINYLOXY) 3 CHLOROPHENYL] 3 (2 NITROBENZOYL)UREA; ABT 963; ALBENDAZOLE; AMPRENAVIR; APREPITANT; ATAZANAVIR; ATENOLOL; BAICALEIN; CARBAMAZEPINE; CARBENDAZIM; CILOSTAZOL; CIMETIDINE; CURCUMIN; CYCLODEXTRIN; CYCLOSPORIN A; DANAZOL; DIGOXIN; ER 34122; ETRAVIRINE; EVEROLIMUS; FELODIPINE; FENOFIBRATE; GRISEOFULVIN; IBUPROFEN; ISOTRETINOIN; ITRACONAZOLE; LAB 687; LOPINAVIR PLUS RITONAVIR; MEBENDAZOLE; MEGESTROL ACETATE; METFORMIN; METOPROLOL; MFB 1041; N [4 [6 [4 (TRIFLUOROMETHYL)PHENYL] 4 PYRIMIDINYLOXY]BENZOTHIAZOL 2 YL]ACETAMIDE; NABILONE; NILVADIPINE; NIMODIPINE; NITRENDIPINE; PG 301029; PROPRANOLOL; RAPAMYCIN; RETINOIC ACID; RITONAVIR; ROSUVASTATIN; SAQUINAVIR; TACROLIMUS; THEOPHYLLINE; TIPRANAVIR; TRANILAST; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AREA UNDER THE CURVE; BIOPHARMACEUTICS CLASSIFICATION SYSTEM; COMPLEX FORMATION; CRYSTALLIZATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG SOLUBILITY; EMULSION; HUMAN; NONHUMAN; PARTICLE SIZE; PH; PHARMACEUTICAL ENGINEERING; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW;

EID: 80054697161     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2011.08.032     Document Type: Short Survey

References (105)

1. G.L. Amidon, H. Lennernas, V.P. Shah, and J.R. Crison A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability Pharmaceutical Research 12 1995 413 420
2. P. Artursson, K. Palm, and K. Luthman Caco-2 monolayers in experimental and theoretical predictions of drug transport Advanced Drug Delivery Reviews 46 2001 27 43
3. R.M. Atkinson, C. Bedford, K.J. Child, and E.G. Tomich Effect of particle size on blood griseofulvin-levels in man Nature 193 1962 588 589
4. A. Avdeef Solubility of sparingly-soluble ionizable drugs Advanced Drug Delivery Reviews 59 2007 568 590 (Pubitemid 47285405)
5. S.I. Badawy, D.B. Gray, F. Zhao, D. Sun, A.E. Schuster, and M.A. Hussain Formulation of solid dosage forms to overcome gastric pH interaction of the factor Xa inhibitor, BMS-561389 Pharmaceutical Research 23 2006 989 996 (Pubitemid 43781407)
6. S.I. Badawy, and M.A. Hussain Microenvironmental pH modulation in solid dosage forms Journal of Pharmaceutical Sciences 96 2007 948 959 (Pubitemid 46797467)
7. A. Bak, A. Gore, E. Yanez, M. Stanton, S. Tufekcic, R. Syed, A. Akrami, M. Rose, S. Surapaneni, T. Bostick, A. King, S. Neervannan, D. Ostovic, and A. Koparkar The co-crystal approach to improve the exposure of a water-insoluble compound: AMG 517 sorbic acid co-crystal characterization and pharmacokinetics Journal of Pharmaceutical Sciences 97 2008 3942 3956
8. N. Blagden, M. de Matas, P.T. Gavan, and P. York Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates Advanced Drug Delivery Reviews 59 2007 617 630 (Pubitemid 47285407)
9. M.E. Brewster, and T. Loftsson Cyclodextrins as pharmaceutical solubilizers Advanced Drug Delivery Reviews 59 2007 645 666 (Pubitemid 47299263)
10. Y. Chen, G.G. Zhang, J. Neilly, K. Marsh, D. Mawhinney, and Y.D. Sanzgiri Enhancing the bioavailability of ABT-963 using solid dispersion containing Pluronic F-68 International Journal of Pharmaceutics 286 2004 69 80 (Pubitemid 39410474)
11. Y. Chiba, N. Kohri, K. Iseki, and K. Miyazaki Improvement of dissolution and bioavailability for mebendazole, an agent for human echinococcosis, by preparing solid dispersion with polyethylene glycol Chemical & Pharmaceutical Bulletin 39 1991 2158 2160
12. S.L. Childs, G.P. Stahly, and A. Park The salt-cocrystal continuum: the influence of crystal structure on ionization state Molecular Pharmaceutics 4 2007 323 338 (Pubitemid 46983949)
13. W.L. Chiou, and S. Riegelman Pharmaceutical applications of solid dispersion systems Journal of Pharmaceutical Sciences 60 1971 1281 1302
14. J. Cook, W. Addicks, and Y.H. Wu Application of the biopharmaceutical classification system in clinical drug development - an industrial view The AAPS Journal 10 2008 306 310
15. R.M. Dannenfelser, H. He, Y. Joshi, S. Bateman, and A.T. Serajuddin Development of clinical dosage forms for a poorly water soluble drug I: Application of polyethylene glycol-polysorbate 80 solid dispersion carrier system Journal of Pharmaceutical Sciences 93 2004 1165 1175 (Pubitemid 38529690)
16. EMEA, 2010. Guideline on the investigation of bioequivalence. Avaiable at: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/ 2010/01/WC500070039.pdf (Last accessed 13 April 2011).
17. M.G. Fakes, B.J. Vakkalagadda, F. Qian, S. Desikan, R.B. Gandhi, C. Lai, A. Hsieh, M.K. Franchini, H. Toale, and J. Brown Enhancement of oral bioavailability of an HIV-attachment inhibitor by nanosizing and amorphous formulation approaches International Journal of Pharmaceutics 370 2009 167 174
18. A. Fasano Innovative strategies for the oral delivery of drugs and peptides Trends in Biotechnology 16 1998 152 157
19. FDA, 2000. Guidance for Industry, Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Available at: http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070246.pdf (Last accessed 13 April 2011).
20. K. Fukushima, S. Terasaka, K. Haraya, S. Kodera, Y. Seki, A. Wada, Y. Ito, N. Shibata, N. Sugioka, and K. Takada Pharmaceutical approach to HIV protease inhibitor atazanavir for bioavailability enhancement based on solid dispersion system Biological & Pharmaceutical Bulletin 30 2007 733 738 (Pubitemid 46571002)
21. E. Galia, J. Horton, and J.B. Dressman Albendazole generics - a comparative in vitro study Pharmaceutical Research 16 1999 1871 1875 (Pubitemid 30040704)
22. F. Gimenez, C. Fernandez, and A. Mabondzo Transport of HIV protease inhibitors through the blood-brain barrier and interactions with the efflux proteins, P-glycoprotein and multidrug resistance proteins Journal of Acquired Immune Deficiency Syndrome 36 2004 649 658 (Pubitemid 38685958)
23. R.N. Gursoy, and S. Benita Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs Biomedicine & Pharmacotherapy 58 2004 173 182 (Pubitemid 38479922)
24. H.R. Guzman, M. Tawa, Z. Zhang, P. Ratanabanangkoon, P. Shaw, C.R. Gardner, H. Chen, J.P. Moreau, O. Almarsson, and J.F. Remenar Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations Journal of Pharmaceutical Sciences 96 2007 2686 2702 (Pubitemid 47597818)
25. A. Hanafy, H. Spahn-Langguth, G. Vergnault, P. Grenier, M. Tubic Grozdanis, T. Lenhardt, and P. Langguth Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug Advanced Drug Delivery Reviews 59 2007 419 426 (Pubitemid 47260709)
26. B.C. Hancock, and M. Parks What is the true solubility advantage for amorphous pharmaceuticals? Pharmaceutical Research 17 2000 397 404 (Pubitemid 30395293)
27. C.X. He, Z.G. He, and J.Q. Gao Microemulsions as drug delivery systems to improve the solubility and the bioavailability of poorly water-soluble drugs Expert Opinion on Drug Delivery 7 2010 445 460
28. X. He, L. Pei, H.H. Tong, and Y. Zheng Comparison of spray freeze drying and the solvent evaporation method for preparing solid dispersions of baicalein with pluronic F68 to improve dissolution and oral bioavailability AAPS PharmSciTech 2010
29. J. Hecq, M. Deleers, D. Fanara, H. Vranckx, P. Boulanger, S. Le Lamer, and K. Amighi Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed poorly water-soluble weak base European Journal of Pharmaceutics and Biopharmaceutics 64 2006 360 368 (Pubitemid 44585201)
30. D. Horter, and J.B. Dressman Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract Advanced Drug Delivery Reviews 46 2001 75 87
31. L.F. Huang, and W.Q. Tong Impact of solid state properties on developability assessment of drug candidates Advanced Drug Delivery Reviews 56 2004 321 334
32. S. Jamzad, and R. Fassihi Role of surfactant and pH on dissolution properties of fenofibrate and glipizide - a technical note AAPS PharmSciTech 7 2006 E33
33. L. Jia, H. Wong, C. Cerna, and S.D. Weitman Effect of nanonization on absorption of 301029: ex vivo and in vivo pharmacokinetic correlations determined by liquid chromatography/mass spectrometry Pharmaceutical Research 19 2002 1091 1096 (Pubitemid 34984991)
34. L. Jia, H. Wong, Y. Wang, M. Garza, and S.D. Weitman Carbendazim: disposition, cellular permeability, metabolite identification, and pharmacokinetic comparison with its nanoparticle Journal of Pharmaceutical Sciences 92 2003 161 172 (Pubitemid 36042307)
35. J. Jinno, N. Kamada, M. Miyake, K. Yamada, T. Mukai, M. Odomi, H. Toguchi, G.G. Liversidge, K. Higaki, and T. Kimura Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs Journal of Controlled Release 111 2006 56 64 (Pubitemid 43289995)
36. J. Jinno, N. Kamada, M. Miyake, K. Yamada, T. Mukai, M. Odomi, H. Toguchi, G.G. Liversidge, K. Higaki, and T. Kimura In vitro-in vivo correlation for wet-milled tablet of poorly water-soluble cilostazol Journal of Controlled Release 130 2008 29 37
37. H.N. Joshi, R.W. Tejwani, M. Davidovich, V.P. Sahasrabudhe, M. Jemal, M.S. Bathala, S.A. Varia, and A.T. Serajuddin Bioavailability enhancement of a poorly water-soluble drug by solid dispersion in polyethylene glycol-polysorbate 80 mixture International Journal of Pharmaceutics 269 2004 251 258 (Pubitemid 38032837)
38. A.J. Jounela, P.J. Pentikainen, and A. Sothmann Effect of particle size on the bioavailability of digoxin European Journal of Clinical Pharmacology 8 1975 365 370
39. M.S. Jung, J.S. Kim, M.S. Kim, A. Alhalaweh, W. Cho, S.J. Hwang, and S.P. Velaga Bioavailability of indomethacin-saccharin cocrystals The Journal of Pharmacy and Pharmacology 62 2010 1560 1568
40. T. Kai, Y. Akiyama, S. Nomura, and M. Sato Oral absorption improvement of poorly soluble drug using solid dispersion technique Chemical & Pharmaceutical Bulletin 44 1996 568 571 (Pubitemid 26103123)
41. A.M. Kaushal, P. Gupta, and A.K. Bansal Amorphous drug delivery systems: molecular aspects, design, and performance Critical Reviews in Therapeutic Drug Carrier System 21 2004 133 193 (Pubitemid 41647581)
42. Y. Kawabata, K. Yamamoto, K. Debari, S. Onoue, and S. Yamada Novel crystalline solid dispersion of tranilast with high photostability and improved oral bioavailability European Journal of Pharmaceutical Sciences 39 2010 256 262
43. M. Kennedy, J. Hu, P. Gao, L. Li, A. Ali-Reynolds, B. Chal, V. Gupta, C. Ma, N. Mahajan, A. Akrami, and S. Surapaneni Enhanced bioavailability of a poorly soluble VR1 antagonist using an amorphous solid dispersion approach: a case study Molecular Pharmaceutics 5 2008 981 993
44. F. Kesisoglou, S. Panmai, and Y. Wu Nanosizing - oral formulation development and biopharmaceutical evaluation Advance Drug Delivery Review 59 2007 631 644 (Pubitemid 47285408)
45. K. Kohli, S. Chopra, D. Dhar, S. Arora, and R.K. Khar Self-emulsifying drug delivery systems: an approach to enhance oral bioavailability Drug Discovery Today 15 2010 958 965
46. N. Kohri, Y. Yamayoshi, H. Xin, K. Iseki, N. Sato, S. Todo, and K. Miyazaki Improving the oral bioavailability of albendazole in rabbits by the solid dispersion technique The Journal of Pharmacy and Pharmacology 51 1999 159 164 (Pubitemid 29131308)
47. N. Kondo, T. Iwao, K. Hirai, M. Fukuda, K. Yamanouchi, K. Yokoyama, M. Miyaji, Y. Ishihara, K. Kon, and Y. Ogawa Improved oral absorption of enteric coprecipitates of a poorly soluble drug Journal of Pharmaceutical Sciences 83 1994 566 570 (Pubitemid 24222385)
48. N. Kondo, T. Iwao, H. Masuda, K. Yamanouchi, Y. Ishihara, N. Yamada, T. Haga, Y. Ogawa, and K. Yokoyama Improved oral absorption of a poorly water-soluble drug, HO-221, by wet-bead milling producing particles in submicron region Chemical & Pharmaceutical Bulletin 41 1993 737 740 (Pubitemid 23166149)
49. H. Kranz, C. Guthmann, T. Wagner, R. Lipp, and J. Reinhard Development of a single unit extended release formulation for ZK 811 752, a weakly basic drug European Journal of Pharmaceutical Sciences 26 2005 47 53 (Pubitemid 41097260)
50. M.S. Ku Use of the biopharmaceutical classification system in early drug development The AAPS Journal 10 2008 208 212
51. M.S. Ku, and W. Dulin A biopharmaceutical classification-based Right-First-Time formulation approach to reduce human pharmacokinetic variability and project cycle time from First-In-Human to clinical Proof-Of-Concept Pharmaceutical Development & Technology 2010 1 18
52. Y. Kubo, Y. Terashima, N. Yagi, H. Nochi, K. Tamoto, and H. Sekikawa Enhanced bioavailability of probucol following the administration of solid dispersion systems of probucol-polyvinylpyrrolidone in rabbits Biological & Pharmaceutical Bulletin 32 2009 1880 1884
53. I. Kushida, M. Ichikawa, and N. Asakawa Improvement of dissolution and oral absorption of ER-34122, a poorly water-soluble dual 5-lipoxygenase/ cyclooxygenase inhibitor with anti-inflammatory activity by preparing solid dispersion Journal of Pharmaceutical Sciences 91 2002 258 266 (Pubitemid 34074484)
54. J.P Lakshman, Y. Cao, J. Kowalski, and A.T. Serajuddin Application of melt extrusion in the development of a physically and chemically stable high-energy amorphous solid dispersion of a poorly water-soluble drug Molecular Pharmaceutics 5 2008 994 1002
55. D. Law, E.A. Schmitt, K.C. Marsh, E.A. Everitt, W. Wang, J.J. Fort, S.L. Krill, and Y. Qiu Ritonavir-PEG 8000 amorphous solid dispersions: in vitro and in vivo evaluations Journal of Pharmaceutical Sciences 93 2004 563 570 (Pubitemid 38332289)
56. S. Li, S. Wong, S. Sethia, H. Almoazen, Y.M. Joshi, and A.T. Serajuddin Investigation of solubility and dissolution of a free base and two different salt forms as a function of pH Pharmaceutical Research 22 2005 628 635 (Pubitemid 40603261)
57. C.A. Lipinski Drug-like properties and the causes of poor solubility and poor permeability Journal of Pharmacological and Toxicological Methods 44 2000 235 249 (Pubitemid 32239479)
58. C.A. Lipinski, F. Lombardo, B.W. Dominy, and P.J. Feeney Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Advanced Drug Delivery Reviews 46 2001 3 26 (Pubitemid 33653411)
59. C. Liu, J. Wu, B. Shi, Y. Zhang, T. Gao, and Y. Pei Enhancing the bioavailability of cyclosporine a using solid dispersion containing polyoxyethylene (40) stearate Drug Development and Industrial Pharmacy 32 2006 115 123 (Pubitemid 43220920)
60. G.G. Liversidge, and K.C. Cundy Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs International Journal of Pharmaceutics 125 1995 91 97
61. R. Lobenberg, and G.L. Amidon Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards European Journal of Pharmaceutics and Biopharmaceutics 50 2000 3 12 (Pubitemid 30326685)
62. T. Loftsson, and M.E. Brewster Pharmaceutical applications of cyclodextrins. 1: Drug solubilization and stabilization Journal of Pharmaceutical Sciences 85 1996 1017 1025 (Pubitemid 26338912)
63. R.H. Müller, and K. Peters Nanosuspensions for the formulation of poorly soluble drugs: I. Preparation by a size-reduction technique International Journal of Pharmaceutics 160 1998 229 237 (Pubitemid 28083096)
64. D.P. McNamara, S.L. Childs, J. Giordano, A. Iarriccio, J. Cassidy, M.S. Shet, R. Mannion, E. O'Donnell, and A. Park Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API Pharmaceutical Research 23 2006 1888 1897 (Pubitemid 44200553)
65. M. Mosharraf, and C. Nyström The effect of particle size and shape on the surface specific dissolution rate of microsized practically insoluble drugs International Journal of Pharmaceutics 122 1995 35 47
66. E.A. Mueller, J.M. Kovarik, J.B. van Bree, W. Tetzloff, J. Grevel, and K. Kutz Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation Pharmaceutical Research 11 1994 301 304 (Pubitemid 24076228)
67. M. Newa, K.H. Bhandari, J.O. Kim, J.S. Im, J.A. Kim, B.K. Yoo, J.S. Woo, H.G. Choi, and C.S. Yong Enhancement of solubility, dissolution and bioavailability of ibuprofen in solid dispersion systems Chemical & Pharmaceutical Bulletin 56 2008 569 574 (Pubitemid 351520145)
68. N. Ni, T. Sanghvi, and S. Yalkowsky Solubilization and preformulation of carbendazim International Journal of Pharmaceutics 244 2002 99 104 (Pubitemid 35245450)
69. S. Onoue, H. Sato, K. Ogawa, Y. Kawabata, T. Mizumoto, K. Yuminoki, N. Hashimoto, and S. Yamada Improved dissolution and pharmacokinetic behavior of cyclosporine A using high-energy amorphous solid dispersion approach International Journal of Pharmaceutics 399 2010 94 101
70. S. Onoue, H. Takahashi, Y. Kawabata, Y. Seto, J. Hatanaka, B. Timmermann, and S. Yamada Formulation design and photochemical studies on nanocrystal solid dispersion of curcumin with improved oral bioavailability Journal of Pharmaceutical Sciences 99 2010 1871 1881
71. S. Onoue, A. Uchida, H. Takahashi, Y. Seto, Y. Kawabata, K. Ogawa, K. Yuminoki, N. Hashimoto, and S. Yamada Development of high-energy amorphous solid dispersion of nanosized nobiletin, a citrus polymethoxylated flavone, with improved oral bioavailability Journal of Pharmaceutical Sciences 100 2011 3793 3801
72. M. Pudipeddi, and A.T. Serajuddin Trends in solubility of polymorphs Journal of Pharmaceutical Sciences 94 2005 929 939 (Pubitemid 40780760)
73. R.A. Rajewski, and V.J. Stella Pharmaceutical applications of cyclodextrins. 2: In vivo drug delivery Journal of Pharmaceutical Sciences 85 1996 1142 1169 (Pubitemid 26372882)
74. B. Rodriguez-Spong, C.P. Price, A. Jayasankar, A.J. Matzger, and N. Rodriguez-Hornedo General principles of pharmaceutical solid polymorphism: a supramolecular perspective Advanced Drug Delivery Reviews 56 2004 241 274 (Pubitemid 38201425)
75. A. Scholz, B. Abrahamsson, S.M. Diebold, E. Kostewicz, B.I. Polentarutti, A.L. Ungell, and J.B. Dressman Influence of hydrodynamics and particle size on the absorption of felodipine in labradors Pharmaceutical Research 19 2002 42 46 (Pubitemid 34075105)
76. N. Schultheiss, and A. Newman Pharmaceutical cocrystals and their physicochemical properties Crystal Growth Design 9 2009 2950 2967
77. A.T. Serajuddin Salt formation to improve drug solubility Advanced Drug Delivery Reviews 59 2007 603 616 (Pubitemid 47285406)
78. R. Shegokar, and R.H. Muller Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives International Journal of Pharmaceutics 399 2010 129 139
79. S. Sinha, M. Ali, S. Baboota, A. Ahuja, A. Kumar, and J. Ali Solid dispersion as an approach for bioavailability enhancement of poorly water-soluble drug ritonavir AAPS PharmSciTech 11 2010 518 527
80. V.J. Stella, and K.W. Nti-Addae Prodrug strategies to overcome poor water solubility Advance Drug Delivery Review 59 2007 677 694 (Pubitemid 47285410)
81. G.A. Stephenson, A. Aburub, and T.A. Woods Physical stability of salts of weak bases in the solid-state Journal of Pharmaceutical Sciences 100 2011 1607 1617
82. A. Streubel, J. Siepmann, A. Dashevsky, and R. Bodmeier pH-independent release of a weakly basic drug from water-insoluble and -soluble matrix tablets Journal of Controlled Release 67 2000 101 110 (Pubitemid 30201685)
83. K. Sugano, Y. Nabuchi, M. Machida, and Y. Aso Prediction of human intestinal permeability using artificial membrane permeability International Journal of Pharmaceutics 257 2003 245 251 (Pubitemid 36507050)
84. Y. Sun, Y. Rui, Z. Wenliang, and X. Tang Nimodipine semi-solid capsules containing solid dispersion for improving dissolution International Journal of Pharmaceutics 359 2008 144 149
85. J.P. Sylvestre, M.C. Tang, A. Furtos, G. Leclair, M. Meunier, and J.C. Leroux Nanonization of megestrol acetate by laser fragmentation in aqueous milieu Journal of Controlled Release 149 2011 273 280
86. T. Takagi, C. Ramachandran, M. Bermejo, S. Yamashita, L.X. Yu, and G.L. Amidon A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan Molecular Pharmaceutics 3 2006 631 643 (Pubitemid 46087480)
87. A.S. Tatavarti, and S.W. Hoag Microenvironmental pH modulation based release enhancement of a weakly basic drug from hydrophilic matrices Journal of Pharmaceutical Sciences 95 2006 1459 1468 (Pubitemid 44049115)
88. M. Thanou, J.C. Verhoef, and H.E. Junginger Chitosan and its derivatives as intestinal absorption enhancers Advanced Drug Delivery Reviews 50 Suppl. 1 2001 S91 S101
89. H.H. Tonnesen, M. Masson, and T. Loftsson Studies of curcumin and curcuminoids, XXVII. Cyclodextrin complexation: solubility, chemical and photochemical stability International Journal of Pharmaceutics 244 2002 127 135 (Pubitemid 35245453)
90. P.H. Tran, T.T. Tran, K.H. Lee, D.J. Kim, and B.J. Lee Dissolution-modulating mechanism of pH modifiers in solid dispersion containing weakly acidic or basic drugs with poor water solubility Expert Opinion on Drug Delivery 7 2010 647 661
91. B. Van Eerdenbrugh, M. Van Speybroeck, R. Mols, K. Houthoofd, J.A. Martens, L. Froyen, J. Van Humbeeck, P. Augustijns, and G. Van den Mooter Itraconazole/TPGS/Aerosil200 solid dispersions: characterization, physical stability and in vivo performance European Journal of Pharmaceutical Sciences 38 2009 270 278
92. T. Vasconcelos, B. Sarmento, and P. Costa Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs Drug Discovery Today 12 2007 1068 1075 (Pubitemid 350186132)
93. J.M. Vaughn, J.T. McConville, M.T. Crisp, K.P. Johnston, and R.O. Williams 3rd Supersaturation produces high bioavailability of amorphous danazol particles formed by evaporative precipitation into aqueous solution and spray freezing into liquid technologies Drug Development and Industrial Pharmacy 32 2006 559 567
94. D.A. Volpe Variability in Caco-2 and MDCK cell-based intestinal permeability assays Journal of Pharmaceutical Sciences 97 2008 712 725 (Pubitemid 351293876)
95. B. Wahlang, Y.B. Pawar, and A.K. Bansal Identification of permeability-related hurdles in oral delivery of curcumin using the Caco-2 cell model European Journal of Pharmaceutics and Biopharmaceutics 77 2011 275 282
96. WHO, 2006. Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability. Annex. 7, WHO Technical Report Series 937. Available at: http://whqlibdoc.who.int/trs/WHO-TRS- 937-eng.pdf (Last accessed 13 April 2011).
97. C.Y. Wu, and L.Z. Benet Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system Pharmaceutical Research 22 2005 11 23 (Pubitemid 40558141)
98. Y. Wu, A. Loper, E. Landis, L. Hettrick, L. Novak, K. Lynn, C. Chen, K. Thompson, R. Higgins, U. Batra, S. Shelukar, G. Kwei, and D. Storey The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human International Journal of Pharmaceutics 285 2004 135 146 (Pubitemid 39361543)
99. D. Xia, F. Cui, H. Piao, D. Cun, Y. Jiang, M. Ouyang, and P. Quan Effect of crystal size on the in vitro dissolution and oral absorption of nitrendipine in rats Pharmaceutical Research 27 2010 1965 1976
100. K. Yamashita, T. Nakate, K. Okimoto, A. Ohike, Y. Tokunaga, R. Ibuki, K. Higaki, and T. Kimura Establishment of new preparation method for solid dispersion formulation of tacrolimus International Journal of Pharmaceutics 267 2003 79 91 (Pubitemid 37352952)
101. K. Yoshizuka, H. Ohta, K. Inoue, H. Kitazaki, and M. Ishimaru Selective separation of flavonoids with a polyvinyl alcohol membrane Journal of Membrane Science 118 1996 41 48
102. N. Zerrouk, C. Chemtob, P. Arnaud, S. Toscani, and J. Dugue In vitro and in vivo evaluation of carbamazepine-PEG 6000 solid dispersions International Journal of Pharmaceutics 225 2001 49 62 (Pubitemid 32728199)
103. G.G. Zhang, R.F. Henry, T.B. Borchardt, and X. Lou Efficient co-crystal screening using solution-mediated phase transformation Journal of Pharmaceutical Sciences 96 2007 990 995 (Pubitemid 46797470)
104. G.G. Zhang, D. Law, E.A. Schmitt, and Y. Qiu Phase transformation considerations during process development and manufacture of solid oral dosage forms Advanced Drug Delivery Reviews 56 2004 371 390 (Pubitemid 38202329)
105. X. Zheng, R. Yang, Y. Zhang, Z. Wang, X. Tang, and L. Zheng Part II: bioavailability in beagle dogs of nimodipine solid dispersions prepared by hot-melt extrusion Drug Development and Industrial Pharmacy 33 2007 783 789 (Pubitemid 47123804)